Clinical decision support · for licensed clinicians
Offer peptide therapy with
the evidence behind you.
Pepacorn is the clinical intelligence platform for peptide and precision medicine. For any condition, see current graded research, what patients and peer clinicians are actually reporting, and the safety cautions that matter — across peptides, Rx, and hormones. You keep every clinical decision.
KPV — NF-κB pathway, does not trigger MRGPRX2 · PMID 19909746
reduced flushing & GI flares
at 12 weeks · real-world outcomes
Built on 97 agents · 350+ PubMed-verified citations · 23 conditions · a machine-enforced safety engine.
The problem
Your patients are already asking. The answers are scattered.
A patient asks about a peptide they read about. The literature is thin and buried, the forums are noisy and unreliable, and nothing shows you what actually worked in another clinician’s patient. So you either turn them away or spend hours you don’t have. Pepacorn puts the credible signal — evidence, community, and peers — in one place, organized the way you actually think: by the condition in front of you.
How clinicians use it
Start with the condition. See what’s known. Decide.
Search the patient’s presentation — endometriosis, MCAS, insulin resistance, low-T, cognitive decline. Pepacorn routes it to the right therapeutic options and shows each one across three tiers, ranked by fit, with the cautions already applied.
Published evidence
Every option graded strong / emerging / preclinical, each claim tied to a real, PubMed-verified citation — not a marketing link.
What patients report
Structured real-world signal — doses, effects, sentiment, and how many independent reports corroborate it.
What your peers see
De-identified outcomes from other clinicians on the platform. The data no textbook has.
The full toolkit
Real protocols aren’t just peptides. Neither are we.
Pepacorn covers the compounds clinicians actually reach for — 78 peptides alongside the relevant prescription drugs, hormones, and evidence-based supplements (GLP-1s, low-dose naltrexone, metformin, HRT, inositol, berberine, and more). Because the right answer for a patient is often a combination, and it should be graded and checked for interactions the same way.
Safety by design
A safety engine that reads the rules for you.
“Avoid LL-37 in MCAS” isn’t a sentence buried in a monograph — it’s a rule Pepacorn applies before it shows you anything. Contraindications, dose-reduction flags, and monitoring warnings fire automatically against your patient’s conditions. You can override a clinical caution with your judgment — it’s logged — while anything a pharmacy legally can’t compound is gated out entirely. Every compound carries its current 503A / compounding status.
Clinician-in-the-loop, always. Pepacorn surfaces and warns; you decide and prescribe.
Contraindication — cationic peptides in MCAS
LL-37, VIP and full α-MSH degranulate mast cells via MRGPRX2 — avoid in mast-cell patients.
KPV is safe here (NF-κB pathway). The engine knows the difference — and offers the safe alternative in the same view.
Run it in your practice
From a patient’s question to a protocol you can run.
Build a protocol from the intelligence engine, tailor dose and duration, capture off-label consent, chart the encounter, and export a clean script you prescribe through your own pharmacy channel. Track outcomes over time — and every outcome you log makes the peer network smarter for everyone.
Why you can trust it
Verified, not scraped.
Every citation in Pepacorn was checked against PubMed — real PMID, real DOI, real finding. Unreliable vendor links and consumer forum claims were deliberately left out. Grades are honest: strong means human trials, preclinical means preclinical. When the evidence is thin, we say so.
Offer peptide therapy you can stand behind.
Explore the full intelligence engine on a 14-day trial — no PHI, no card to start.